Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invesco Biotechnology & Genome ETF (NY:PBE)

98.54 +0.45 (+0.46%)
Official Closing Price Updated: 4:10 PM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Invesco Biotechnology & Genome ETF

News headline image
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk. 
Via The Motley Fool
Topics ETFs
News headline image
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? ↗
PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a fraction of the cost. 
Via The Motley Fool
Topics ETFs
News headline image
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better. 
Via The Motley Fool
Topics ETFs
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗
Via Stocktwits
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion ↗
Via Stocktwits
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease ↗
Via Stocktwits
News headline image
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist? ↗
PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility. 
Via The Motley Fool
Topics ETFs
News headline image
VHT vs. PBE: Which Health Care ETF Is the Better Buy? ↗
PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost... 
Via The Motley Fool
Topics ETFs
News headline image
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus. 
Via Stocktwits
News headline image
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
News headline image
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential ↗
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts. 
Via InvestorPlace
News headline image
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of... 
Via Benzinga
News headline image
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
News headline image
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
News headline image
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
News headline image
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗
 
Via Benzinga
News headline image
US Judge Weighs Nationwide Ban On Abortion Pills ↗
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is... 
Via Benzinga
News headline image
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗
 
Via Benzinga
News headline image
7 Best Biotech Stocks to Buy in July 2022 ↗
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
News headline image
Biotech ETFs That Outperformed Last Week ↗
Though the broad U.S. market saw a tumultuous ride last week with most of the sectors in red, biotechnology was the biggest gainer. 
Via Talk Markets
News headline image
A Comprehensive Guide To Genomic ETFs ↗
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
News headline image
5 Top ETFs With Exposure To Biogen ↗
Here is a look at five ETFs with large exposure to Biogen shares. 
Via Talk Markets
News headline image
5 Top ETFs With Exposure To Biogen ↗
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
News headline image
3 Biotech Stocks Wall Street Predicts Will Rally By 45% Or More ↗
Wall Street analysts expect the biotech industry to grow significantly soon, with the biotech stocks Organogenesis (ORGO​​​​​​​), BioDelivery Sciences (BDSI) and Champions Oncology (CSBR) gaining more... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.